Treatment of Wegener's Granulomatosis With Cyclophosphamide
Treatment of Wegener's Granulomatosis With Cyclophosphamide
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis
 who have already entered the study, and to treat new patients. The investigators will attempt
 to correlate the clinical response with specific immunosuppressive effects of drug
 administration. The investigators are accumulating data on the optimal duration and side
 effects of therapy.
The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis
 who have already entered the study, and to treat new patients. The investigators will attempt
 to correlate the clinical response with specific immunosuppressive effects of drug
 administration. The investigators are accumulating data on the optimal duration and side
 effects of therapy.

 Age Range: greater than 1 year
Patients greater than 1 year of age with the clinical and pathological diagnosis of WG
 whose illness presents a risk of permanent disability or death. Examples of processes that
 impart risk of permanent disability or death include: peripheral and central nervous system
 disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal
 organs.

 No women who are pregnant or intend to become pregnant.

 No patients who have known malignancies.

 Patients must be HIV negative.